Daniel O. Claassen, MD, MS

Despite a few surprising program failures early this year, there is plenty of potential worth holding on to in the Huntington disease pipeline.

The associate professor of neurology at Vanderbilt University Medical Center offered his perspective on the feasibility of genotyping, phasing, and targeting of SNPs in Huntington disease.

The associate professor of neurology at Vanderbilt University Medical Center spoke to the findings of a recent study in Huntington disease that assessed the feasibility of selectively knocking down mutant protein expression.

The associate professor of neurology at Vanderbilt University Medical Center offered his perspective on his and colleagues’ study of single nucleotide polymorphisms in Huntington disease.